Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.

[1]  B. Markova,et al.  Detection of CMY-99, a Novel Acquired AmpC-Type β-Lactamase, and VIM-1 in Proteus mirabilis Isolates in Bulgaria , 2013, Antimicrobial Agents and Chemotherapy.

[2]  D. Hoban,et al.  Antimicrobial susceptibility of inpatient urinary tract isolates of gram-negative bacilli in the United States: results from the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2011. , 2013, Clinical therapeutics.

[3]  Ray-Jade Chen,et al.  Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. , 2013, International journal of antimicrobial agents.

[4]  P. Hsueh,et al.  Distribution of Extended-Spectrum β-Lactamases, AmpC β-Lactamases, and Carbapenemases among Enterobacteriaceae Isolates Causing Intra-Abdominal Infections in the Asia-Pacific Region: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) , 2013, Antimicrobial Agents and Chemotherapy.

[5]  N. Singla,et al.  Occurrence and phenotypic detection of class A carbapenemases among Escherichia coli and Klebsiella pneumoniae blood isolates at a tertiary care center. , 2013, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[6]  Michael Bell,et al.  Vital Signs: Carbapenem-Resistant Enterobacteriaceae , 2013, MMWR. Morbidity and mortality weekly report.

[7]  Chi-Yu Chen,et al.  Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. , 2012, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[8]  J. Chia,et al.  Outcomes and characteristics of ertapenem-nonsusceptible Klebsiella pneumoniae bacteremia at a university hospital in Northern Taiwan: a matched case-control study. , 2012, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[9]  W. Ko,et al.  Clinical characteristics of urosepsis caused by extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumonia and their emergence in the community. , 2012, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[10]  F. G. Rosa,et al.  The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria , 2011, Infection.

[11]  W. Ko,et al.  Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae. , 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[12]  V. Tam,et al.  Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Fadda,et al.  Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment , 2007, Antimicrobial Agents and Chemotherapy.

[14]  R. Thomson,,et al.  Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella Species , 2006, Antimicrobial Agents and Chemotherapy.

[15]  P. Larsson,et al.  In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals , 2006, Scandinavian journal of infectious diseases.

[16]  G. Rossolini,et al.  Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum β-Lactamases , 2005, Antimicrobial Agents and Chemotherapy.

[17]  V L Yu,et al.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. , 1991, Annals of internal medicine.

[18]  J. McCue.  Gram‐Negative Bacillary Bacteremia in the Elderly: Incidence, Ecology, Etiology, and Mortality , 1987, Journal of the American Geriatrics Society.

[19]  J. Chander,et al.  Epidemiology of extended-spectrum β-lactamase, AmpC, and carbapenemase production in Proteus mirabilis. , 2014, Japanese journal of infectious diseases.

[20]  Y. Funayama,et al.  Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[21]  P. Fey,et al.  Extended Spectrum β-Lactamase (ESBL)-Producing Enterobacteriaceae , 2012, Drugs.

[22]  L. Peterson,et al.  Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.